Sulfatides facilitate apolipoprotein E-mediated amyloid-β peptide clearance through an endocytotic pathway

Journal of Neurochemistry

Volumn 106, Issue 3, 2008, Pages 1275-1286

  Zeng, Youchun ^a   Han, Xianlin ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid clearance; Apolipoprotein E; Endocytosis; Sulfatide

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; GALACTOSE; SULFATE; SULFATIDE;

ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; NEUROBLASTOMA CELL; NEUROCHEMISTRY; PEPTIDE ANALYSIS; PRIORITY JOURNAL;

AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEINS E; CATTLE; CELL LINE, TUMOR; DRUG SYNERGISM; ENDOCYTOSIS; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION; SULFOGLYCOSPHINGOLIPIDS; TRANSPORT VESICLES;

EID: 48249111789     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05481.x     Document Type: Article

References (43)

1. Arelin K., Kinoshita A., Whelan C. M., Irizarry M. C., Rebeck G. W., Strickland D. K. Hyman B. T. (2002) LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res. Mol. Brain Res. 104, 38 46.
2. Bales K. R., Verina T., Dodel R. C. et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17, 263 264.
3. Bales K. R., Dodart J. C., DeMattos R. B., Holtzman D. M. Paul S. M. (2002) Apolipoprotein E, amyloid, and Alzheimer disease. Mol. Interv. 2, 363 375.
4. Bateman R. J., Munsell L. Y., Morris J. C., Swarm R., Yarasheski K. E. Holtzman D. M. (2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856 861.
5. Castillo G. M., Lukito W., Wight T. N. Snow A. D. (1999) The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J. Neurochem. 72, 1681 1687.
6. Cedazo-Minguez A. Cowburn R. F. (2001) Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J. Cell. Mol. Med. 5, 254 266.
7. Cheng H., Xu J., McKeel D. W. Jr Han X. (2003) Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study. Cell. Mol. Biol. 49, 809 818.
8. Cheng H., Jiang X. Han X. (2007) Alterations in lipid homeostasis of mouse dorsal root ganglia induced by apolipoprotein E deficiency: a shotgun lipidomics study. J. Neurochem. 101, 57 76.
9. Fagan A. M., Watson M., Parsadanian M., Bales K. R., Paul S. M. Holtzman D. M. (2002) Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9, 305 318.
10. von Figura K., Gieselmann V. Jaeken J. (2001) Metachromatic leukodystrophy: lysosomal disorders, in The Metabolic and Molecular Bases of Inherited Diseases (Sachdev H. S., Beaudet A. L., Sly W. S. Valle D., eds 8th Edn, pp. 3695 3724. McGraw-Hill, New York.
11. Fraser P. E., Nguyen J. T., Chin D. T. Kirschner D. A. (1992) Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J. Neurochem. 59, 1531 1540.
12. Han X. (2005) Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2, 65 77.
13. Han X. (2007) Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stages of Alzheimer's disease: a tale of shotgun lipidomics. J. Neurochem. 103 (Suppl. 1 171 179.
14. Han X., Holtzman D. M., McKeel D. W. Jr, Kelley J. Morris J. C. (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 82, 809 818.
15. Han X., Cheng H., Fryer J. D., Fagan A. M. Holtzman D. M. (2003a) Novel role for apolipoprotein E in the central nervous system: modulation of sulfatide content. J. Biol. Chem. 278, 8043 8051.
16. Han X., Fagan A. M., Cheng H., Morris J. C., Xiong C. Holtzman D. M. (2003b) Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann. Neurol. 54, 115 119.
17. Hartman R. E., Izumi Y., Bales K. R., Paul S. M., Wozniak D. F. Holtzman D. M. (2005) Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 25, 6213 6220.
18. Hayashi H., Campenot R. B., Vance D. E. Vance J. E. (2007) Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. J. Neurosci. 27, 1933 1941.
19. Holtzman D. M., Fagan A. M., Mackey B., Tenkova T., Sartorius L., Paul S. M., Bales K., Ashe K. H., Irizarry M. C. Hyman B. T. (2000a) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47, 739 747.
20. Holtzman D. M., Bales K. R., Tenkova T. et al. (2000b) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 2892 2897.
21. van Horssen J., Wilhelmus M. M., Heljasvaara R., Pihlajaniemi T., Wesseling P., de Waal R. M. Verbeek M. M. (2002) Collagen XVIII: a novel heparan sulfate proteoglycan associated with vascular amyloid depositions and senile plaques in Alzheimer's disease brains. Brain Pathol. 12, 456 462.
22. Kalanj-Bognar S., Rundek T., Furac I., Demarin V. Cosovic C. (2002) Leukocyte lysosomal enzymes in Alzheimer's disease and Down's syndrome. J. Gerontol. A Biol. Sci. Med. Sci. 57, B16 B21.
23. Kang D. E., Pietrzik C. U., Baum L. et al. (2000) Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Invest. 106, 1159 1166.
24. LaDu M. J., Falduto M. T., Manelli A. M., Reardon C. A., Getz G. S. Frail D. E. (1994) Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 269, 23403 23406.
25. Marcus J., Honigbaum S., Shroff S., Honke K., Rosenbluth J. Dupree J. L. (2006) Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia 53, 372 381.
26. Matsuzaki K. (2007) Physicochemical interactions of amyloid beta-peptide with lipid bilayers. Biochim. Biophys. Acta 1768, 1935 1942.
27. McGeer E. G. McGeer P. L. (2003) Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 741 749.
28. Molander-Melin M., Pernber Z., Franken S., Gieselmann V., Mansson J. E. Fredman P. (2004) Accumulation of sulfatide in neuronal and glial cells of arylsulfatase A deficient mice. J. Neurocytol. 33, 417 427.
29. Murphy M. P., Das P., Nyborg A. C. et al. (2003) Overexpression of nicastrin increases Abeta production. FASEB J. 17, 1138 1140.
30. Nixon R. A. (2005) Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol. Aging 26, 373 382.
31. Qiu Z., Strickland D. K., Hyman B. T. Rebeck G. W. (2001) Elevation of LDL receptor-related protein levels via ligand interactions in Alzheimer disease and in vitro. J. Neuropathol. Exp. Neurol. 60, 430 440.
32. Schneider A., Rajendran L., Honsho M., Gralle M., Donnert G., Wouters F., Hell S. W. Simons M. (2008) Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J. Neurosci. 28, 2874 2882.
33. Selkoe D. J. (2006) The ups and downs of Abeta. Nat. Med. 12, 758 759.
34. Snow A. D., Mar H., Nochlin D., Sekiguchi R. T., Kimata K., Koike Y. Wight T. N. (1990) Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. Am. J. Pathol. 137, 1253 1270.
35. Strittmatter W. J. Roses A. D. (1996) Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 19, 53 77.
36. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S. Roses A. D. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1977 1981.
37. Tokuda T., Calero M., Matsubara E. et al. (2000) Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem. J. 348 (Pt. 2 359 365.
38. Vos J. P., Lopes-Cardozo M. Gadella B. M. (1994) Metabolic and functional aspects of sulfogalactolipids. Biochim. Biophys. Acta 1211, 125 149.
39. Wisniewski T. Frangione B. (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135, 235 238.
40. Yanagisawa K., Odaka A., Suzuki N. Ihara Y. (1995) GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1, 1062 1066.
41. Zeng Y., Han X. Gross R. W. (1999) Phospholipid-subclass-specific partitioning of lipophilic ions in membrane-water systems. Biochem. J. 338, 651 658.
42. Zeng Y., Cheng H., Jiang X. Han X. (2008) Endosomes and lysosomes play distinct roles in sulfatide-induced neuroblastoma apoptosis: potential mechanisms contributing to abnormal sulfatide metabolism in related neuronal diseases. Biochem. J. 410, 81 92.
43. Zerbinatti C. V., Wahrle S. E., Kim H., Cam J. A., Bales K., Paul S. M., Holtzman D. M. Bu G. (2006) Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J. Biol. Chem. 281, 36180 36186.